Natixis Advisors, L.P. Kymera Therapeutics, Inc. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 14,334 shares of KYMR stock, worth $585,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,334
Previous 14,072
1.86%
Holding current value
$585,543
Previous $566,000
30.74%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding KYMR
# of Institutions
182Shares Held
67.6MCall Options Held
223KPut Options Held
241K-
Price T Rowe Associates Inc Baltimore, MD6.7MShares$274 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.46MShares$264 Million2.86% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$245 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$245 Million1.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.23MShares$214 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.23B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...